Browse the evidence

Genetic variants (SNPs) associated with obesity have modest individual effects, but aggregated into genetic risk scores, they can interact with environmental factors (diet, activity) to amplify obesity risk.

Your genes play a role in your weight, but they are not the whole story. Environmental factors like diet and activity can amplify genetic risk. Managing these factors is crucial for those with a genetic predisposition to obesity.

Pharmacogenomics can partially explain heterogeneous responses to weight loss medications by identifying genetic variants that affect drug metabolism or receptor binding.

Current weight loss medications work differently for different people, partly due to genetics. While pharmacogenomic testing is not yet standard, it holds promise for predicting who will benefit from specific drugs like topiramate or liraglutide.

Exogenous oxytocin administration reduces body weight and food intake in diet-induced obese rodents and non-human primates by acting on oxytocin receptors in the hindbrain (NTS) and hypothalamus to enhance satiety signals and increase energy expenditure.

Research suggests oxytocin may help reduce food intake and increase energy expenditure in obese individuals, particularly those with leptin resistance. However, current human trials are short-term, and long-term safety and optimal dosing (especially via intranasal spray) are still being determined. It is not yet a standard, widely available treatment for obesity.

GLP-1RA users tend to overconsume saturated fat and total fat percentages, potentially exacerbating gastrointestinal side effects like nausea and constipation.

You are likely eating too much saturated fat, which can worsen nausea and constipation common with GLP-1RA. Try to shift some calories from fats to fiber-rich carbohydrates and protein to improve GI comfort and nutrient density.

Post-exercise high-fat feeding suppresses p70S6K1 activity in human skeletal muscle, potentially impairing muscle protein synthesis and remodeling despite adequate protein intake.

If your goal is maximizing muscle growth or remodeling after training, consuming a high-fat meal immediately post-exercise may blunt the signaling pathways (p70S6K1) responsible for building muscle, even if you eat enough protein. Consider prioritizing carbohydrates or lower-fat protein sources in the immediate recovery window to optimize anabolic signaling.

Females have higher T2DM-related mortality rates than males globally, although males show a greater rate of increase in Disability-Adjusted Life Years (DALYs) over time.

Be aware that women face higher T2DM mortality rates than men globally. While men are seeing a faster rise in disease burden, women currently bear a heavier mortality toll. Both sexes should prioritize prevention, but women may need to be particularly vigilant about early diagnosis and management.

A higher polygenic score for BMI is associated with lower weight loss following bariatric surgery, although the effect size is modest and attenuates in sensitivity analyses.

If you are considering bariatric surgery, having a high genetic risk for obesity might mean you lose slightly less weight than someone with low genetic risk. However, the surgery is still very effective. You may need to be more vigilant with lifestyle changes or consider adjunct therapies like GLP-1 RAs to maintain your results.

A dietary pattern high in fruit, dairy products, and sweets is associated with lower blood pressure, lower urinary albumin excretion (UAE), and lower brachial-ankle pulse wave velocity (baPWV) in T2DM patients.

A diet high in fruit, dairy, and sweets is associated with lower blood pressure and arterial stiffness (baPWV) in T2DM patients. This benefit may come from nutrients in fruit (antioxidants, fiber) and dairy (calcium, potassium, magnesium), which may offset the negative effects of sweets. However, this is an observational finding and does not recommend increasing sugar intake.

Obese gut microbial communities exhibit higher branched-chain amino acid (BCAA) catabolism and hexanoic acid production, which may negatively impact energy balance and metabolic health.

Obese gut bacteria may metabolize proteins differently, producing metabolites like hexanoic acid that could affect energy balance. This highlights why metabolic health in obesity is complex and not just about calorie intake.

Inhibitors of hepatic lipogenesis (including ACLY, ACC, FAS, SCD1, and DGAT2 inhibitors) reduce liver fat content in MASLD, but some (like ACC inhibitors) may increase serum triglycerides, necessitating combination therapies (e.g., ACC + DGAT2 inhibitors) to mitigate adverse lipid effects.

Several new drugs target the liver's fat-making enzymes (like ACC and FAS). While they reduce liver fat, some can raise blood triglycerides. To avoid this, doctors may combine an ACC inhibitor with a DGAT2 inhibitor. These are still largely in clinical trials and are not yet first-line treatments compared to GLP-1 agonists.

Higher visceral adiposity, quantified by the Lipid Accumulation Product (LAP), is strongly associated with an increased risk of declined renal function (eGFR < 60 mL/min/1.73m2) in the general population, independent of traditional risk factors like diabetes and hypertension.

To protect your kidney function, focus on reducing visceral fat, not just total body weight. Use the Lipid Accumulation Product (LAP) concept: combine your waist circumference with your Triglyceride levels. A high LAP score indicates higher visceral fat and a significantly higher risk of kidney dysfunction, even if your BMI is normal. Managing this requires lifestyle interventions like caloric restriction and physical activity to lower both waist size and triglycerides.

Long-term adherence to low-carbohydrate diets, particularly those high in saturated fats, is associated with increased LDL-cholesterol, increased cardiovascular disease risk, and increased mortality.

If you choose a low-carb diet, prioritize unsaturated fats (like olive oil, nuts, fish) over saturated fats (like red meat, butter) to protect your heart health and avoid raising LDL-cholesterol.

In healthy adults, higher dietary saturated fat intake is independently associated with higher LDL-C, but this relationship is not dose-dependent across typical intake ranges and is largely explained by abdominal visceral adipose tissue (VAT) mass rather than the fat itself.

If you are healthy and have a normal BMI, simply reducing saturated fat might not significantly lower your LDL-C if you have high visceral fat. Focus on overall body composition and visceral fat reduction, as these factors appear to drive LDL-C levels more strongly than SFA intake alone in this population.

SGLT2 inhibitors reduce hepatic lipid content and liver enzymes in patients with MASLD and Type 2 Diabetes, but histological evidence for treating MASH is still required.

If you have diabetes and fatty liver, SGLT2 inhibitors (like dapagliflozin) are a good option to lower liver fat and enzymes. They work by changing how your body handles sugar and fat. However, they are not yet proven to reverse the scarring of MASH, so they are part of a broader management strategy.

Long-term high-level endurance training does not preserve or enhance the capacity for myofibrillar protein synthesis (iMyoPS) in response to unaccustomed resistance exercise in older adults compared to untrained age-matched peers.

If you are an older adult who has done endurance sports for decades, don't assume your muscles will automatically build or maintain mass when you start lifting weights. Your history of running or cycling does not protect you from 'anabolic resistance' to resistance exercise. You likely need to approach resistance training with the same diligence as an untrained peer, focusing on progressive overload and adequate protein intake, as your chronic training history offers no special advantage in muscle protein synthesis rates.

Weekly GLP-1 receptor agonists significantly reduce MACE risk in obese T2DM patients, whereas daily GLP-1 RAs do not show a significant reduction compared to placebo.

For obese diabetic patients, choosing a weekly GLP-1 injection (like dulaglutide or semaglutide) may offer better heart protection than daily options (like liraglutide or lixisenatide), according to this analysis. However, the difference between the two classes was not statistically significant when compared directly to each other.

The peptide triple agonist GEP44, targeting GLP-1, Y1, and Y2 receptors, promotes profound weight loss and glycemic control in diet-induced obese rats without triggering the nausea or malaise associated with standard GLP-1 receptor agonists.

This research highlights a promising new class of drugs (triple agonists like GEP44) that may offer superior weight loss and blood sugar control compared to current GLP-1 medications, without causing the nausea that often stops people from taking them. However, this is currently only proven in animals, not humans. For now, standard GLP-1s remain the primary option, but patients experiencing intolerable side effects might discuss clinical trials or future availability of these multi-agonists with their healthcare provider.

Co-treatment with omega-3 polyunsaturated fatty acids (EPA, DPA, or DHA) mitigates palmitate-induced lipotoxicity in skeletal muscle cells, preserving cell viability, preventing apoptosis, and maintaining mitochondrial membrane integrity.

In a cellular context, high levels of saturated fats (like palmitate) can damage muscle cells, causing them to die and stop growing. Omega-3 fatty acids (EPA, DHA, DPA) can protect these cells from this damage. Specifically, DPA was found to fully preserve cell viability and mitochondrial integrity, while EPA and DHA offered partial protection. This suggests that adequate omega-3 intake may help counteract some negative effects of high saturated fat diets on muscle health at a cellular level.

Meal timing is not associated with body composition (fat mass, lean mass, or BMI) in young adults, regardless of sex.

Changing when you eat will not directly change your weight or body fat percentage. Focus on total calorie intake and exercise for body composition changes. However, timing may still be useful for metabolic health markers like insulin sensitivity.

GLP-1RAs activate neurons in the paraventricular nucleus (PVH) and ventromedial hypothalamus (VMH) to suppress food intake and increase energy expenditure or thermogenesis.

GLP-1 medications also target other brain regions (PVH and VMH) to suppress food intake and increase energy expenditure. This helps explain why these medications can lead to weight loss even without significant changes in diet or exercise.

Continuing lifestyle interventions (diet/exercise) after stopping AOMs does not prevent significant weight regain, as this subgroup also showed significant regain.

Even if you maintain a healthy diet and exercise routine, stopping anti-obesity medication is likely to lead to weight regain. The biological effects of the medication are significant, and lifestyle changes alone may not be enough to counteract the regain.

Relying solely on Fasting Plasma Glucose (FPG) for diagnosis misses a significant number of diabetes cases in Korean populations; OGTT or HbA1c is required for accurate diagnosis.

If you are Asian or have a lower body weight, a normal fasting blood sugar might not mean you are safe. You may have high blood sugar after eating. Ask your doctor about an OGTT or HbA1c test if you have risk factors.

HbA1c is a valid diagnostic criterion for diabetes (≥6.5%) in Korea, but it should not be used alone due to lower detection rates compared to combined FPG and OGTT.

HbA1c is a convenient test that doesn't require fasting, but it might miss diabetes if used alone. For the most accurate diagnosis, especially if you have conditions like anemia or kidney disease, combine it with fasting glucose or an OGTT.

Macrophage-specific lipoprotein lipase (LPL) promotes atherosclerosis by acting as a bridging molecule for remnant lipoprotein uptake, leading to foam cell formation and plaque progression.

LPL helps clear fat from blood, but in immune cells within artery walls, it helps build plaques. Therapies targeting LPL must distinguish between clearing blood fat (good) and feeding artery plaques (bad).